Healthcare Industry News: Elekta
News Release - December 23, 2008
Elekta to Supply the Bank of Cyprus Oncology Centre With Advanced Radiation Therapy Treatment Systems for Cancer CareNew Systems To Improve The Quality And Throughput Of Patients' Treatments
STOCKHOLM, Sweden, December 23 -- (Healthcare Sales & Marketing Network) -- The Bank of Cyprus Oncology Centre (BOCOC, Nicosia, Cyprus) recently announced the acquisition of two Elekta Synergy® systems and an Elekta Synergy® Platform for the non-invasive treatment of cancer. The systems will be delivered throughout 2009, with the first installation expected to begin in March. The acquisition was made with the help of a donation from the Bank of Cyprus Medical Foundation
The first Elekta Synergy® system will be installed into a newly-built bunker providing the hospital, for the first time, with capabilities such as whole-body Image Guided Radiotherapy (IGRT), Stereotactic Radiotherapy (SRT) with a suite of specialized stereotactic accessories, and Intensity Modulated Radiotherapy (IMRT) using Volumetric Modulated Arc Therapy (VMAT) technology. Second and third Elekta linear accelerators will be installed into existing bunkers replacing two Siemens linear accelerators.
"We have high expectations from our new collaboration with Elekta," says Dr. Chris Constantinou, Director of Medical Physics at the BOCOC, adding: "Key factors for our decision included our positive evaluation of Elekta's fully-digital architecture enabling use of remote service functionality through Intellimax, the performance of XVI for advanced IGRT applications, the offered comprehensive set of equipment for Stereotactic Radiotherapy and Radiosurgery applications and not least VMAT which promises to significantly improve both the quality and throughput of our patients' treatments."
The centre will also upgrade their existing oncology information system to Elekta's comprehensive oncology charting solution, MOSAIQ® from Impac Software.
"We considered MOSAIQ® to be a natural successor to our existing Lantis network and we were impressed by Elekta's professional appreciation of and commitment to our need to maintain and seamlessly upgrade our existing patient database," Dr. Constantinou added.
Dr. Demetris Andreopoulos, Director of Radiation Oncology of the BOCOC, further commented, "The Bank of Cyprus Oncology Center in Nicosia services the needs for cancer treatment for the entire Cypriot population of just under one million people. Our decision in favor of Elekta therefore followed a very careful evaluation of all the factors that would maximize both the clinical efficacy and quality of the services we offer. We felt that with its offered package Elekta addressed successfully these key factors and we look forward to a positive and fruitful collaboration with them as our new partners for the benefit of all the patients we treat."
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated state of the art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.
Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to help in the cure of cancer patients with curable disease and to improve the quality of life of those patients with metastatic disease, making the future possible today.
Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.
Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb.
For more information about Elekta, please visit www.Elekta.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.